Cambrex & Astrazeneca Hold Ceremony To Mark Long-term Supply Agreement At Karlskoga, Sweden Facility

East Rutherford, NJ – January 16, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.

Cambrex AstraZeneca ribbon cutting

Left to right front row: Alexandra Pichard Nielsen, Director, Sales & Business Development, Cambrex; Per Kanto, National Sales Manager, Sweden, AstraZeneca; Juliette White, VP of Global External Sourcing, AstraZeneca; Bjarne Sandberg, Managing Director, Cambrex Karlskoga (ribbon cutting); Fredrik Härtfelder, Head of Supplier Management, AstraZeneca; Magnus Sjögren, Head of New Supply API, AstraZeneca; Päivi Tolstoy, New Product Project Manager, Cambrex.
Left to right back row: Dean Powney, Supplier Director, AstraZeneca; Fredrik Stenberg, Product Manager, Cambrex; Tomas Sjöberg, Manager, Plant Development & Support, Cambrex; Martin Brink, Supply Chain Lead, AstraZeneca; Jeroen Koningen, Project Manager, AstraZeneca; Johan Kårehag, Global Category Manager, AstraZeneca; Stephan Haitz, VP, Sales & Business Development, Cambrex; Mattias Magnusson, Senior Lean Coach, AstraZeneca.

The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.

Speaking at the ceremony, Juliette White, VP Global External Sourcing, AstraZeneca, commented, “Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery.” She added “We look forward to a successful collaboration with Cambrex.”

Shawn Cavanagh, COO of Cambrex, stated, “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products.” He added, “We will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand.”

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. 

Cambrex’s Karlskoga, site develops and manufactures small molecule APIs, new chemical entities (NCEs) and intermediates from grams to tons, through all phases of the drug lifecycle.

Home to a team of more than 400 employees, the site is comprised of a combination of GMP and non-GMP work, providing classic and advanced chemistry capabilities, continuous processes and high energy chemistry expertise.

The site also features a wide range of flexible manufacturing facilities including kilo scale, pilot scale and large scale commercial production plants.

For more information, please visit

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.

Contact: Alex Maw

Director, Marketing and Communications, Cambrex

Tel: +44 7803 443 155


Posted by Hannah McLachlan